Review



gene exp pdgfa hs00234994 m1  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Thermo Fisher gene exp pdgfa hs00234994 m1
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Gene Exp Pdgfa Hs00234994 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/Gene+Exp%2E+PDGFA%2C+Hs00234994_m1/pmc12931375-249-23--1
    Average 91 stars, based on 1 article reviews
    gene exp pdgfa hs00234994 m1 - by Bioz Stars, 2026-11
    91/100 stars

    Images

    1) Product Images from "Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis"

    Article Title: Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis

    Journal: Journal of Human Immunity

    doi: 10.70962/jhi.20250011

    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Figure Legend Snippet: Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

    Techniques Used: Activation Assay, Expressing, Generated, Two Tailed Test

    Related Articles

    other:

    Article Title: miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma
    Article Snippet: Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn from Dana-Farber Cancer Institute of Harvard Medical School) were derived as previously described and maintained in SAGM media (Lonza, Cat #CC-3118).

    Article Title: Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
    Article Snippet: Frozen tumors were manually dissociated using a TissueLyser 181 (Qiagen).

    Article Title: miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.
    Article Snippet: Primary 3D cultures of a lung cancer PDX tumour (PDX_LU_10) were established at BIDMC of Harvard Medical School and maintained in advanced DMEM/F12 (Gibco, cat. no. 12634-010) supplemented with 1× Glutamax (Gibco, cat. no. 35050-061), 1× HEPES (Gibco, cat. no. 15630080), 1.25 mM N-acetylcysteine (Sigma-Aldrich, cat. no. A9165), 10 mM nicotinamide (Sigma-Aldrich, cat. no. N0636), 10 μM forskolin (Sigma-Aldrich, cat. no. F6886), 1× B27 (Gibco, cat. no. 17504-044), 5 ng/ml Noggin (Sigma-Aldrich, cat. no. PHC1506), 100 ng/ml FGF10 (Gibco, cat. no. PHG0204), 20 ng/ml FGF2 (Gibco, cat. no. PHG0026), 50 ng/ml EGF (Gibco, cat. no. 10605-HNAE-250), 10 ng/ml PDGFA (Gibco, cat. no. PHG0035), 10 ng/ml FGF7 (Gibco, cat. no. PHG0094), 1% penicillin–streptomycin and 10 μM Y-27632 (Selleck Chemicals, cat. no. S1049).

    Expressing:

    Article Title: Zoledronic Acid Abrogates Restraint Stress-Induced Macrophage Infiltration, PDGF-AA Expression, and Ovarian Cancer Growth
    Article Snippet: .. We investigated overall survival (OS) and progression-free survival (PFS) in patients with high and low expression of PDGFA and ENA78 ( CXCL5 ) (Affymetrix IDs: 205463_s_at and 215101_s_at, Thermo). ..



    Similar Products

    93
    Bioss pdgfa bs 0196r primary antibodies
    Pdgfa Bs 0196r Primary Antibodies, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/PDGF+A+Polyclonal+Antibody/pm42101574-126-15-19
    Average 93 stars, based on 1 article reviews
    pdgfa bs 0196r primary antibodies - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    91
    Thermo Fisher gene exp pdgfa hs00234994 m1
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Gene Exp Pdgfa Hs00234994 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/Gene+Exp%2E+PDGFA%2C+Hs00234994_m1/pmc12931375-249-23--1
    Average 91 stars, based on 1 article reviews
    gene exp pdgfa hs00234994 m1 - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    87
    Thermo Fisher gene exp pdgfa rn00709363 m1
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Gene Exp Pdgfa Rn00709363 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/Gene+Exp%2E+Pdgfa%2C+Rn00709363_m1/pm41699868-64-52--1
    Average 87 stars, based on 1 article reviews
    gene exp pdgfa rn00709363 m1 - by Bioz Stars, 2026-11
    87/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology anti pdgfa
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Anti Pdgfa, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/PDGF-A/pm41604576-465-36-40
    Average 93 stars, based on 1 article reviews
    anti pdgfa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    99
    Thermo Fisher gene exp pdgfa mm01205760 m1
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Gene Exp Pdgfa Mm01205760 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/Gene+Exp%2E+Pdgfa%2C+Mm01205760_m1/pm41576455-80-45--1
    Average 99 stars, based on 1 article reviews
    gene exp pdgfa mm01205760 m1 - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology pdgfa
    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( <t>PDGFA</t> , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
    Pdgfa, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdgfa/PDGF-A+Antibody/pm41147949-118-46-48
    Average 93 stars, based on 1 article reviews
    pdgfa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

    Journal: Journal of Human Immunity

    Article Title: Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis

    doi: 10.70962/jhi.20250011

    Figure Lengend Snippet: Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

    Article Snippet: The probes used were the following: TGFB1 Hs07289533_m1, ISG15 Hs01921425_s1, IFIT1 Hs03027069_s1, IFI27 Hs01086373_g1, SIGLEC1 Hs00988063_m1, MX1 Hs00895608_m1, FGF-2 Hs00266645_m1, ITGB6 Hs00168458_m1, PDGFA Hs00234994_m1.

    Techniques: Activation Assay, Expressing, Generated, Two Tailed Test